Search
Gilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigational[A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. … [A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.
Erdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigationalIn early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for … personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the development of more personalized and precise medicines tailoring to
Bretylium
go.drugbank.com/drugs/DB01158ApprovedRecent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site. … The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels.
Synonyms: 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium, N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminiumDisulfiram
go.drugbank.com/drugs/DB00822ApprovedInvestigationalIt is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. … It acts by inhibiting aldehyde dehydrogenase.
Synonyms: N,N,N',N'-tetraethylthiuram disulfide, 1,1'-dithiobis(N,N-diethylthioformamide)Roxithromycin
go.drugbank.com/drugs/DB00778ApprovedInvestigationalWithdrawnRoxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. … It was shown to be more effective against certain Gram-negative bacteria, particularly _Legionella pneumophila_.
Synonyms: (9E)-erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime)International brands: Neo-Suxigal, Ao Ge ShenBitolterol
go.drugbank.com/drugs/DB00901ApprovedWithdrawnBitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.
Synonyms: 4-(2-(tert-butylamino)-1-hydroxyethyl)-o-phenylene di-p-toluate, 4-[2-(tert-butylamino)-1-hydroxyethyl]-o-phenylene di-p-toluateAmmonia
go.drugbank.com/drugs/DB11118ApprovedInvestigationalIt is present in normally present in all tissues constituting a metabolic pool, where it is mostly taken up by glutamic acid and take part in transamination and other reactions, including the synthesis … of protein by the Krebs-Hanseleit cycle in the liver [L2033].
Products: Go TimeNavepegritide
go.drugbank.com/drugs/DB17824ApprovedInvestigational[L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065] … Achondroplasia, the most prevalent skeletal dysplasia, is caused by a gain-of-function variant in the fibroblast growth factor receptor 3 (FGFR3), which leads to overactive downstream signaling that inhibits
Crisaborole
go.drugbank.com/drugs/DB05219ApprovedInvestigationalCrisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. … This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older.
Leniolisib
go.drugbank.com/drugs/DB16217ApprovedInvestigational[L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections … The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).